Allspring Global Investments Holdings LLC Sells 173,233 Shares of DexCom, Inc. $DXCM

Allspring Global Investments Holdings LLC lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 44.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 212,361 shares of the medical device company’s stock after selling 173,233 shares during the period. Allspring Global Investments Holdings LLC’s holdings in DexCom were worth $17,749,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. SWS Partners bought a new stake in DexCom during the second quarter worth about $1,661,000. Baader Bank Aktiengesellschaft bought a new stake in DexCom during the second quarter worth about $393,000. Mn Services Vermogensbeheer B.V. raised its holdings in DexCom by 4.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock worth $12,797,000 after acquiring an additional 6,800 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in DexCom by 85.7% during the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock worth $105,469,000 after acquiring an additional 557,576 shares in the last quarter. Finally, Shell Asset Management Co. raised its holdings in DexCom by 16.8% during the second quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock worth $3,126,000 after acquiring an additional 5,138 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Robert W. Baird dropped their target price on DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, September 26th. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Morgan Stanley boosted their price target on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Citigroup lowered their price target on DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $97.00.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock worth $564,733 over the last three months. Company insiders own 0.32% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $66.60 on Friday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The stock’s 50 day moving average is $73.35 and its 200-day moving average is $77.52. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $26.12 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 1.39 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the business earned $0.43 earnings per share. The firm’s revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.